Nicholas Investment Partners, LP Incyte Corp Transaction History

Nicholas Investment Partners, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$74.18 - $108.93 $1.96 Million - $2.88 Million	-26,459 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$63.18 - $85.97 $831,638 - $1.13 Million	13,163 Added 99.0%	26,459 $1.94 Million
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $1.38 Million - $1.81 Million	-18,925 Reduced 58.73%	13,296 $1.16 Million
Q3 2019 Nov 13, 2019	BUY	$72.82 - $86.52 $11,432 - $13,583	157 Added 0.49%	32,221 $2.39 Million
Q2 2019 Aug 09, 2019	SELL	$73.52 - $88.7 $156,450 - $188,753	-2,128 Reduced 6.22%	32,064 $2.72 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $2.17 Million - $3.01 Million	34,192 New	34,192 $2.94 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $2.09 Million - $2.89 Million	-34,383 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $2.37 Million - $2.88 Million	-28,555 Reduced 45.37%	34,383 $2.87 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $2.03 Million - $2.53 Million	-21,702 Reduced 25.64%	62,938 $5.96 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $9.24 Million - $11.7 Million	84,640	84,640 $9.88 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.